Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230684 | 0.88 | PROKR1 (0.43) | PROKR1P2RX3L3MBTL1LMNATP53 | |
| SCHEMBL7429019 | 0.78 | PROKR1 (0.34) | PROKR1P2RX3SRD5A2 | |
| SCHEMBL6943048 | 0.76 | MAPT (0.44) | L3MBTL1LMNATP53MAPT | |
| SCHEMBL6785651 | 0.72 | EGLN1 (0.42) | L3MBTL1 | |
| SCHEMBL6785646 | 0.72 | EGLN1 (0.42) | L3MBTL1 | |
| SCHEMBL6785884 | 0.71 | MAPT (0.40) | L3MBTL1LMNATP53MAPT | |
| SCHEMBL6785879 | 0.71 | MAPT (0.40) | L3MBTL1LMNATP53MAPT | |
| SCHEMBL17750085 | 0.70 | LSS (0.51) | PROKR1SRD5A2L3MBTL1LSSSRD5A1 | |
| SCHEMBL7270758 | 0.69 | ALDH1A1 (0.42) | L3MBTL1LMNA | |
| SCHEMBL6786173 | 0.68 | MMP13 (0.46) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506764-B1 | B-X-(CH2)m-CR1R2-(CH2)n-CO-Y (I) have therapeutic utility as inhibitors of metalloproteinases etc. for medicine by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with | DARWIN DISCOVERY, LTD. (GB) | 2003-01-14 | — | — | US | claimed |
| US-6506764-B1 | B-X-(CH2)m-CR1R2-(CH2)n-CO-Y (I) have therapeutic utility as inhibitors of metalloproteinases etc. for medicine by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with | DARWIN DISCOVERY, LTD. (GB) | 2003-01-14 | — | — | US | disclosed |